AMRI Rebrands as Curia; To Acquire Integrity Bio, LakePharma

By Miranda Greenberg -

July 15, 2021

Albany Molecular Research, Inc. (AMRI), a contract research, development and manufacturing organization, has rebranded and changed its name to Curia. Additionally, Curia has agreed to acquire Integrity Bio, a Thousand Oaks, California-based CDMO and LakePharma, a San Carlos, California-based biologics contract research, development and manufacturing organization (CRDMO).

Along with its name change, the company is introducing a new brand identity, including a new website. The company says the new name reinforces the company’s strategic positioning as an end-to-end global CDMO\ from research and development through to commercial manufacturing. The name Curia is derived from a Latin word for purposeful assembly and references Curia’s patient-focused work. Curia employs more than 3,000 people in 21 locations globally, including more than 600 chemists, 70 biologists, 225 senior scientists, and approximately 400 quality and regulatory specialists.

Acquisition of Integrity Bio

In the first deal, Curia has agreed to acquire Integrity Bio, a CDMO of biologics formulation development and fill–finish manufacturing services. The company recently expanded its facilities to include a second fill-finish line, which more than doubled its manufacturing capacity. Curia currently provides formulation development through fill-finish commercial manufacturing across three center-of-excellence facilities in Albuquerque, New Mexico; Burlington, Massachusetts; and Glasgow, Scotland.

The transaction, which is subject to standard and customary closing conditions, is expected to close in the third quarter.

Acquisition of LakePharma

In a second deal, Curia has agreed to acquire LakePharma, a biologics CRDMO with operations in California, Massachusetts, and Texas. The company specializes in the production and evaluation of DNA vectors, viral vectors, cell lines, proteins, antibodies, mRNA and conjugates. It has six facilities and 235 employees.

The transaction, which is subject to standard and customary closing conditions, is expected to close in the third quarter.

Source: Curia (rebranding), Curia (IntegrityBio acquisition), Curia (LakePharma acquisition), Integrity Bio and LakePharma